Immunovia provides an update on the optimization work to meet the expected performance for commercialization of IMMray™ PanCan-d
Immunovia has today secured blood samples that best conforms to real-life, commercial conditions, which will form the basis for the commercial test model study.LUND, SWEDEN - Immunovia AB (publ) (“Immunovia”) today announced an update on the optimization process to refine the algorithms and eliminate any potential variations for its commercial version of IMMray™ PanCan-d designed for early detection of pancreatic cancer. “The need for further optimization work was previously announced in August 2018 (link to PR ) and during the